Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2010, Article ID 530265, 6 pages
http://dx.doi.org/10.1155/2010/530265
Research Article

Effects of Glycyrrhizic Acid on Peroxisome Proliferator-Activated Receptor Gamma (PPAR ), Lipoprotein Lipase (LPL), Serum Lipid and HOMA-IR in Rats

1School of Science, Monash University, Sunway Campus, 46150, Bandar Sunway, Malaysia
2School of Medicine and Health Sciences, Monash University, Sunway Campus, 46150, Bandar Sunway, Malaysia

Received 30 May 2009; Accepted 28 August 2009

Academic Editor: Joshua K. Ko

Copyright © 2010 Chia Yoke Yin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, “The metabolic syndrome,” The Lancet, vol. 365, no. 9468, pp. 1415–1428, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. P. J. Miranda, R. A. DeFronzo, R. M. Califf, and J. R. Guyton, “Metabolic syndrome: definition, pathophysiology and mechanisms,” American Heart Journal, pp. 33–45, 2005. View at Google Scholar
  3. M. W. Schwartz and S. E. Kahn, “Insulin resistance and obesity,” Nature, vol. 402, no. 6764, pp. 860–861, 1999. View at Google Scholar · View at Scopus
  4. R. J. Mahler and M. L. Adler, “Type 2 diabetes mellitus: update on diagnosis, pathophysiology and treatment,” The Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 4, pp. 1165–1171, 1999. View at Google Scholar · View at Scopus
  5. L. Guo and R. Tabrizchi, “Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance,” Pharmacology & Therapeutics, vol. 111, no. 1, pp. 145–173, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. W. W. Harrington, C. S. Britt, J. G. Wilson et al., “The effect of PPARa , PPARd , PPAR? , and PPARpan agonists on body weight, body mass, and serum lipid profiles in diet-induced obese AKR/J mice,” PPAR Research, vol. 2007, Article ID 97125, 13 pages, 2007. View at Publisher · View at Google Scholar
  7. R. M. Evans, G. D. Barish, and Y. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 1–7, 2004. View at Google Scholar · View at Scopus
  8. J. D. Brown and J. Plutzky, “Peroxisome proliferator activated receptors as transcriptional nodal points and therapeutic targets,” Circulation, pp. 518–533, 2007. View at Google Scholar
  9. I. Dahlman and P. Arner, “Obesity and polymorphisms in genes regulating human adipose tissue,” International Journal of Obesity, vol. 31, no. 11, pp. 1629–1641, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. H. S. Camp, D. Ren, and T. Leff, “Adipogenesis and fat-cell function in obesity and diabetes,” Trends in Molecular Medicine, vol. 8, no. 9, pp. 442–447, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. R. J. Brown and D. J. Rader, “Lipases as modulators of atherosclerosis in murine models,” Current Drug Targets, vol. 8, no. 12, pp. 1307–1319, 2007. View at Google Scholar
  12. Y. Zhang, J. Y. Repa, K. Gauthier, and D. J. Mangelsdorf, “Regulation of lipoprotein lipase by the oxysterol receptors, LXRα and LXRβ,” The Journal of Biological Chemistry, vol. 276, no. 46, pp. 43018–43024, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. B. P. Kota, T. H. Huang, and B. D. Roufogalis, “An overview on biological mechanisms of PPARs,” Pharmacological Research, vol. 51, no. 2, pp. 85–94, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. S. M. Rangwala and M. A. Lazar, “Peroxisome proliferator-activated receptor γ in diabetes and metabolism,” Trends in Pharmacological Sciences, vol. 25, no. 6, pp. 331–336, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. L. A. Baltina, “Chemical modification of glycyrrhizic acid as a route to new bioactive compounds for medicine,” Current Medicinal Chemistry, vol. 10, no. 2, pp. 155–171, 2003. View at Google Scholar · View at Scopus
  16. D. G. Brillante, A. J. O'sullivan, M. T. Johnstone, and L. G. Howes, “Evidence for functional expression of vascular angiotensin II type 2 receptors in patients with insulin resistance,” Diabetes, Obesity & Metabolism, vol. 10, no. 2, pp. 143–150, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972. View at Google Scholar · View at Scopus
  18. H. Takii, T. Kometani, T. Nishimura, T. Nakae, S. Okada, and T. Fushiki, “Antidiabetic effect of glycyrrhizin in genetically diabetic KK-Ay mice,” Biological and Pharmaceutical Bulletin, vol. 24, no. 5, pp. 484–487, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Nakagawa, H. Kishida, N. Arai, T. Nishiyama, and T. Mae, “Licorice flavonoids suppress abdominal fat accumulation and increase in blood glucose level in obese diabetic KK-Ay mice,” Biological and Pharmaceutical Bulletin, vol. 27, no. 11, pp. 1775–1778, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Krätzner, F. Fröhlich, K. Lepler et al., “A peroxisome proliferator-activated receptor ?-retinoid X receptor heterodimer physically interacts with the transcriptional activator PAX6 to inhibit glucagon gene transcription,” Molecular Pharmacology, vol. 73, no. 2, pp. 509–517, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Kageyama, T. Hirano, K. Okada et al., “Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-?,” Biochemical and Biophysical Research Communications, vol. 305, no. 1, pp. 22–27, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. O. Hanyu, T. Miida, K. Obayashi et al., “Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity,” Atherosclerosis, vol. 174, no. 2, pp. 385–390, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. T. M. Wallace, J. C. Levy, and D. R. Matthews, “Use and abuse of HOMA modeling,” Diabetes Care, vol. 27, no. 6, pp. 1487–1495, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. J. P. Berger, T. E. Akiyama, and P. T. Meinke, “PPARs: therapeutic targets for metabolic disease,” Trends in Pharmacological Sciences, vol. 26, no. 5, pp. 244–251, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Berthiaume, M. Laplante, W. T. Festuccia et al., “11beta-HSD1 inhibition improves triglyceridaemia through reduced liver VLDL secretion and partitions lipids towards oxidative tissues,” American Journal of Physiology—Endocrinology and Metabolism, vol. 293, pp. E1045–E1052, 2007. View at Google Scholar
  26. S. P. J. Dullens, J. Plat, and R. P. Mensink, “Increasing apoA-I production as a target for CHD risk reduction,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 17, no. 8, pp. 616–628, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Google Scholar · View at Scopus
  28. K. Schoonjans, J. Peinado-Onsurbe, A. M. Lefebvre et al., “PPARa and PPAR? activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene,” The European Molecular Biology Organization Journal, vol. 15, no. 19, pp. 5336–5348, 1996. View at Google Scholar · View at Scopus
  29. U. A. Boelsterli and M. Bedoucha, “Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPARγ) expression in the liver: insights from models of obesity and type 2 diabetes,” Biochemical Pharmacology, vol. 63, no. 1, pp. 1–10, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. R. A. Memon, L. H. Tecott, K. Nonogaki et al., “Up-regulation of peroxisome proliferator-activated receptors (PPAR-a) and PPAR-? messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-?-responsive adipose tissue-specific genes in the liver of obese diabetic mice,” Endocrinology, vol. 141, no. 11, pp. 4021–4031, 2000. View at Google Scholar · View at Scopus
  31. C. S. Stump, E. J. Henriksen, Y. Wei, and J. R. Sowers, “The metabolic syndrome: role of skeletal muscle metabolism,” Annals of Medicine, vol. 38, pp. 389–402, 2006. View at Google Scholar
  32. B. S. Cha, T. P. Ciaraldi, L. Carter et al., “Peroxisome proliferator-activated receptor (PPAR) ? and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle,” Diabetologia, vol. 44, no. 4, pp. 444–452, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Wang, L. A. Knaub, D. R. Jensen et al., “Skeletal muscle-specific deletion of lipoprotein lipase enhances insulin signaling in skeletal muscle but causes insulin resistance in liver and other tissues,” Diabetes, vol. 58, no. 1, pp. 116–124, 2009. View at Google Scholar
  34. A. D. Dobrian, “The complex role of PPARγ in renal dysfunction in obesity: managing a Janus-faced receptor,” Vascular Pharmacology, vol. 45, no. 1, pp. 36–45, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. B. H. Chung, S. W. Lim, K. O. Ahn et al., “Protective effect of peroxisome proliferator-activated receptor gamma agonist on diabetic and non-diabetic renal diseases,” Nephrology, vol. 10, pp. 40–43, 2005. View at Google Scholar